A memo from Dr Harris to Dr Smithies attached a letter that was sent to all haemophilia centre directors confirming the availability of heated Factor 8 concentrates and advising that there was therefore no longer any need to use un-heat-treated Factor VIII concentrate. Read more about A memo from Dr Harris to Dr Smithies attached a letter that was sent to all haemophilia centre directors confirming the availability of heated Factor 8 concentrates and advising that there was therefore no longer any need to use un-heat-treated Factor VIII concentrate.
An internal DHSS minute, referring to Armour's letter to haemophilia centre directors withdrawing batches of Factorate which had not been donor screened, stated that Rorer Health Care Ltd claimed to be in compliance with their product licence and that the matter had not been treated as a product defect. Read more about An internal DHSS minute, referring to Armour's letter to haemophilia centre directors withdrawing batches of Factorate which had not been donor screened, stated that Rorer Health Care Ltd claimed to be in compliance with their product licence and that the matter had not been treated as a product defect.
In a note from Dr Smithies to Dr Godber, she informed him that the CBLA had announced that they planned to heat all Factor 8 manufactured at BPL/PFL from April 1985. Read more about In a note from Dr Smithies to Dr Godber, she informed him that the CBLA had announced that they planned to heat all Factor 8 manufactured at BPL/PFL from April 1985.
Dr Smithies informed the CMO that she had been told by Dr Dale Lawrence of the CDC that he was seeking a sample of blood from the Lewisham patient. Read more about Dr Smithies informed the CMO that she had been told by Dr Dale Lawrence of the CDC that he was seeking a sample of blood from the Lewisham patient.
Dr Smithies' communication did not suggest any specific knowledge regarding the Armour product or the Lewisham patient. Read more about Dr Smithies' communication did not suggest any specific knowledge regarding the Armour product or the Lewisham patient.
Dr Rotblat contacted the companies manufacturing Factor 8 concentrates to draw together information for the CMO regarding their viral inactivation processes. Read more about Dr Rotblat contacted the companies manufacturing Factor 8 concentrates to draw together information for the CMO regarding their viral inactivation processes.
A report prepared by Dr Rotblat for the CMO repeated Armour's claim that they had done viral inactivation studies "and shown good inactivation". Read more about A report prepared by Dr Rotblat for the CMO repeated Armour's claim that they had done viral inactivation studies "and shown good inactivation".
Dr Harris of Armour described Dr Rotblat as "a valuable ally at the moment" and recorded that "I am now obliged to report Dr Whitmore's patient who sero-converted following treatment with Factorate HT Y69402 to her as Dr Whitmore has confirmed that the patient remains HTLV-III positive." Read more about Dr Harris of Armour described Dr Rotblat as "a valuable ally at the moment" and recorded that "I am now obliged to report Dr Whitmore's patient who sero-converted following treatment with Factorate HT Y69402 to her as Dr Whitmore has confirmed that the patient remains HTLV-III positive."
Professor Bloom issued a questionnaire to haemophilia centre directors. It asked whether (and to what extent) they were still using non-heat-treated product. At a meeting of the AIDS group of UKHCDO directors his analysis was discussed. Read more about Professor Bloom issued a questionnaire to haemophilia centre directors. It asked whether (and to what extent) they were still using non-heat-treated product. At a meeting of the AIDS group of UKHCDO directors his analysis was discussed.
Dr Harris said of heat treatment of Factor VIII in a meeting of the Working Group on AIDS that: "although there is not yet the evidence to guarantee that this is satisfactory; the view was nevertheless unanimous that it should be done." Read more about Dr Harris said of heat treatment of Factor VIII in a meeting of the Working Group on AIDS that: "although there is not yet the evidence to guarantee that this is satisfactory; the view was nevertheless unanimous that it should be done."